Osan Plus (Hydrochlorothiazide, Telmisartan)

Osan Plus combines the diuretic hydrochlorothiazide with the ARB teltel it acts on blood‑pressure regulation pathways. It is indicated for:

• Essential hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertension with fluid retention: improves blood‑pressure control and reduces peripheral edema.
• Diabetic nephropathy : slows the progression of renal impairment associated with diabetes.
• Chronic kidney : helps manage blood‑pressure in patients with chronic kidney disease.
• Heart failure : aids in reducing after‑load and symptomatic fluid overload.
• Stroke risk reduction : contributes to lowering the risk of stroke in high‑risk hypertensive patients.

• Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. Telmisartan blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. The combined effect decreases peripheral resistance and fluid overload, producing a sustained reduction in arterial blood pressure.

Osan Plus may cause a range of adverse reactions. Monitoring and patient education are essential.

Common Side Effects

• Increased urination: more frequent need to void.
• Electrolyte imbalance: low potassium or sodium levels.
• Dizziness or light‑headedness: especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Elevated blood glucose: modest rise in fasting glucose.

Serious or Rare Side Effects

• Severe electrolyte disturbances: hyperkalemia or hyponatremia.
• Acute kidney injury: sudden decline in renal function.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal liver function tests.
• Blood cell disorders: neutropenia or thrombocytopenia.
• Severe hypotension: marked drop in blood pressure causing fainting.

Before starting Osan Plus, consider the following precautions:

• Renal function: assess baseline kidney function and monitor regularly.
• Electrolyte levels: check serum potassium and sodium before and during therapy.
• Diabetes: monitor blood glucose as thiazides may raise glucose levels.
• Gout: be aware of potential uric acid increase that could trigger attacks.
• Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional.
• Store at ambient temperature: keep below 25°C, protect from moisture and light, and retain in original packaging.

Osand ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​  ​  ​  ​  ​ ​ ​ ​ ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​  ​  ​ Major  ​ ​ ​ ​ ​

• Concomitant use with other potent diuretics: risk of severe dehydration and electrolyte loss.
• Co‑administration with ACE inhibitors or other ARBs: additive blood‑pressure lowering, risk of hypotension.
• Lithium therapy: thiazides reduce lithium clearance, increasing toxicity risk.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Cyclosporine or tacrolimus: increased risk of nephrotoxicity.

Moderate ​ 

• Beta‑blockers: may enhance hypotensive effect.
• Antidiabetic drugs: thiazides may raise blood glucose, requiring dose adjustment.
• Anticoagulants (warfarin): thiazides can alter INR stability.",